Clearmind Medicine CMND 深 沪
已收盘 10-24 16:00:00 美东时间
1.01
+0.028
+2.82%
华盛通- 最 高1.02
- 今 开1.01
- 成交量 5.27万股
- 最 低 0.9824
- 昨 收 0.9823
- 总市值 543.32万
- 52周最高 2.18
- 市盈率 静 --
- 换手率 0.98%
- 52周最低 0.80
- 委 比 -45.12%
- 总股本 537.94万
- 历史最高 183.00
- 量 比 0.32
- 振 幅 3.83%
- 历史最低 0.80
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SciSparc and Clearmind’s New Patent Targets Binge Behavior Disorders
SciSparc Ltd. ( ($SPRC) ) has shared an update. On October 20, 2025, SciSparc L...
10-21 02:24
Clearmind Medicine Files US Patent For Psychedelic-Based Therapy Targeting Binge Drinking, Addiction, And Compulsive Behaviors
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major
10-20 19:43
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
SciSparc Ltd. and Clearmind Medicine Inc. have collaboratively published a U.S. patent application for a combination therapy using MEAI and PEA to address binge behavior disorders, including excessive alcohol consumption, eating disorders, and substance addictions. The therapy harnesses MEAI's psychedelic properties and PEA's anti-inflammatory effects, aiming to offer a breakthrough treatment without traditional intervention risks. SciSparc focus...
10-20 11:41
Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
Clearmind Medicine Inc. announce the successful inaugural meeting of its Scientific Advisory Board, focusing on MEAI, their lead candidate for AUD, with potential applications in obesity and mental health. The company highlighted promising safety data and strategic opportunities, supported by a strong IP portfolio of 31 granted patents.
09-25 11:40
Clearmind Medicine Enters $10M Convertible Note Agreement With Institutional Investors, Begins With $555K Issuance At $500K Purchase Price
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major
09-19 20:21
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
Clearmind Medicine Inc., a psychedelic-derived therapeutics company, has entered into securities purchase agreements with institutional investors, enabling them to issue up to $10 million in convertible promissory notes. The Company issued initial notes worth $555,556 for $500,000 and plans to use proceeds for working capital, general corporate purposes, and potential acquisitions to explore strategic opportunities. Aegis Capital Corp. acted as f...
09-19 12:20
Clearmind Medicine Publishes International Patent Application For Therapy Targeting Obesity And Metabolic Syndrome In Collaboration With SciSparc
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major
08-07 19:39
Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
Clearmind Medicine Inc. and SciSparc Ltd. announced a joint international patent application under the PCT for a novel combination therapy targeting metabolic syndrome and obesity. This therapy combines Clearmind's MEAI and SciSparc's PEA, leveraging their complementary pharmacological properties. The collaboration, which has resulted in 13 patent families across multiple jurisdictions, aims to develop innovative treatments for mental health diso...
08-07 11:32
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
SciSparc Ltd. and Clearmind Medicine Inc. have filed a new international patent application for their innovative combination therapy targeting obesity and MASLD. The therapy combines 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) with Palmitoylethanolamide (PEA), leveraging its unique pharmacological properties. The collaboration aims to address significant global health challenges, with obesity affecting over 890 million people and NAFLD...
07-30 12:12
Clearmind Medicine Completes Site Initiation At Tel Aviv Sourasky Medical Center For Phase I/IIa Clinical Trial Evaluating CMND-100, Proprietary Oral Drug Candidate For AUD
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major
07-23 20:56
